| Saturday, September 8 |
| 7:00 AM–5:00 PM |
| |
Registration |
Grand Ballroom Foyer |
| 7:00 AM–6:00 PM |
| |
Speaker Ready Room Open |
Green Room (3rd Floor) |
| 8:00 AM–12:00 Noon |
| |
Workshop 1
New Developments in Genetic Toxicology Testing: The Pig-a Assay
Chairperson: Stephen D. Dertinger, Litron Laboratories and Robert H. Heflich, National Center for Toxicological Research, US FDA
Contributing Sponsor: Bristol-Myers Squibb, Litron Laboratories, and Miltenyi Biotec
Supported in Part by: BioReliance Corporation, Genetic Toxicology Association, and John J. Nicolette |
Auditorium |
| 8:00 AM–8:15 AM |
Introduction to Workshop Goals, Pig-a Assay Terminology and Principles
Robert H. Heflich, National Center for Toxicological Research, US FDA |
|
| 8:15 AM–9:00 AM |
PIG-A Mutations: From the Pathogenesis of PNH to Assessing the Mutation Rate in Humans
Lucio Luzzatto, Istituto Toscano Tumori |
|
| 9:00 AM–9:45 AM |
Update on the International Rat Erythrocyte Pig-a Trial
Stephen D. Dertinger, Litron Laboratories |
|
| 9:45 AM–10:15 AM |
Pig-a, Micronucleus and Comet Assay Combined in a 3-Day Rat Repeated Dose Study with DMBA
Bas-jan M. van der Leede, Janssen R&D |
|
| 10:15 AM–10:30 AM |
Break (Auditorium Foyer) |
|
| 10:30 AM–11:00 AM |
Integration Case Study: 28-Day MNU Study with Multiple Genetox Endpoints
Laura L. Custer, Bristol-Myers Squibb |
|
| 11:00 AM–11:30 AM |
How Well Does the Pig-a Assay Complement Other In Vivo Genetox Assays in Detecting Rodent Carcinogens?
Robert H. Heflich, National Center for Toxicological Research, US FDA |
|
| 11:30 AM–11:50 AM |
Detection of PIGO-Deficient DT40 Cells Using Aerolysin
Jun Nakamura, University of North Carolina at Chapel Hill |
|
| 11:50 AM–12:00 Noon |
Discussion |
|
| 9:30 AM–12:00 Noon |
| |
EMS Executive Board Meeting |
Laurel |
| 12:00 Noon–1:00 PM |
| |
Lunch on Your Own |
|
| 1:00 PM–5:00 PM |
| |
EMS Council Meeting |
Larch |
| 1:00 PM–5:00 PM |
| |
Workshop 2
New Developments in Genetic Toxicology: Automated In Vitro Micronucleus Assay
Chairperson: Steven M. Bryce, Litron Laboratories and Krista L. Dobo, Pfizer Global R&D
Primary Sponsor: Pfizer Global Research and Development and WIL Research
Contributing Sponsor: Litron Laboratories
Supported in Part by: BioReliance Corporation, Genetic Toxicology Association, and John J. Nicolette |
Auditorium |
| 1:00 PM–1:10 PM |
Introduction
Krista L. Dobo, Pfizer Global R&D |
|
| 1:10 PM–1:50 PM |
Automation of the In Vitro Micronucleus Assay Using Flow Cytometry: An Overview
Steven M. Bryce, Litron Laboratories |
|
| 1:50 PM–2:20 PM |
Automated In Vitro Micronucleus Assay for Screening of Pharmaceuticals in TK6 Cells Using Flow Cytometry with 96 Well Plates
Marlies De Boeck, Johnson & Johnson Pharma R&D |
|
| 2:20 PM–2:45 PM |
Break (Auditorium Foyer) |
|
| 2:45 PM–3:25 PM |
Increasing Genotoxicity Screening Capacity: Assessment of Micronucleus Induction with Aneugen/Clastogen Characterization by High Capacity Flow (HCF)
Kim Luu, IntelliCyt Corporation |
|
| 3:25 PM–4:05 PM |
Automation of the In Vitro Primary Human Lymphocyte Micronucleus Assay: Image Analysis versus Flow Cytometry
Azeddine Elhajouji, Novartis Pharma AG |
|
| 4:05 PM–4:45 PM |
Use of Image Analysis to Automate Mechanistic Investigations in the In Vitro MN Assay
Maik J. Schuler, Pfizer Global R&D |
|
| 4:45 PM–5:00 PM |
Discussion |
|
| 1:00 PM–5:00 PM |
| |
Workshop 3
Next Generation Technologies
Chairpersons: Matthew A. Coleman, Lawrence Livermore National Laboratory and Paul Van Hummelen, Center for Cancer Genome Discovery Dana-Farber Cancer Institute
Primary Sponsor: Illumina
Contributing Sponsor: Agilent Technologies |
Grand Ballroom A |
| 1:00 PM–1:10 PM |
Getting a Handle on Starting a NGS Study
Matthew A. Coleman, Lawrence Livermore National Laboratory |
|
| 1:10 PM–1:50 PM |
Genomic Approaches Towards Individualized Cancer Medicine
Paul Van Hummelen, Center for Cancer Genome Discovery Dana Farber Cancer Institute |
|
| 1:50 PM–2:30 PM |
Genomic Studies for Clinical and Genomic Screens
Jay A. Shendure, University of Washington |
|
| 2:30 PM–2:45 PM |
Break (Grand Ballroom Foyer) |
|
| 2:45 PM–3:20 PM |
Detecting New Human Mutations Using Parent-Child Trios: Characteristics and Role in Autism Spectrum Disorders
Brian J. O’Roak, University of Washington |
|
| 3:20 PM–3:55 PM |
Inverse PCR Screen of Leukemogenic Fusiongenes and Analysis by Parallel Sequencing
Andrew T.M. Vaughan, University of California, Davis |
|
| 3:55 PM–4:30 PM |
Sequencing the Transcriptome: Motivations, Workflows, Challenges, and Successes
Mick Correll, Center for Cancer Computational Biology Dana Farber Cancer Institute |
|
| 4:30 PM–5:00 PM |
Concluding Remarks |
|
| 5:00 PM–7:00 PM |
| |
Welcome Reception and Student and
New Investigator Poster Session
Supported in part by: Genetic Toxicology Association |
Evergreen Ballroom E |
| 7:00 PM–7:10 PM |
| |
Opening Keynote Session
Welcome and Opening of the Annual Meeting
Mats Ljungman, The University of Michigan |
Grand Ballroom A |
| 7:10 PM–8:10 PM |
| |
Keynote Lecture 1
Genomic Analysis of Mutations That Appear “Out of the Blue”
Chairperson: Lawrence A. Loeb, University of Washington
Lecturer: Mary-Claire King, University of Washington |
Grand Ballroom A |
| 8:10 PM–9:10 PM |
| |
Keynote Lecture 2
The Key Role of DNA Damage on Cancer, Aging, and Longevity
Chairperson: Philip C. Hanawalt, Stanford University
Lecturer: Jan H.J. Hoeijmakers, Erasmus University |
Grand Ballroom A |
General Information